| Phase 12 trials |
|
Phase 1
|
NCT07710729 |
Jul 2026 → Apr 2027 expected |
obesity disorder |
Novo Nordisk A/S |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07710768 |
Jul 2026 → Apr 2027 expected |
obesity disorder |
Novo Nordisk A/S |
Not yet recruiting
|
No outcome recorded
|
| Phase 26 trials |
|
Phase 2
|
NCT07668388 |
Jun 2026 → Oct 2027 expected |
type 2 diabetes mellitus |
Novo Nordisk A/S |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07395687 |
Feb 2026 → Jan 2027 expected |
obesity disorder |
Novo Nordisk A/S |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07145151 |
Sep 2025 → Jun 2027 expected |
metabolic dysfunction-associated steatohepatitis |
The United Bio-Technology (Hengqin) Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07134335 |
Sep 2025 → Jul 2030 expected |
chronic kidney disease, obesity disorder |
The United Bio-Technology (Hengqin) Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07163624 |
Mar → Nov 2025 |
type 2 diabetes mellitus |
The United Bio-Technology (Hengqin) Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT07177469 |
Mar → Oct 2025 |
obesity disorder |
The United Bio-Technology (Hengqin) Co., Ltd. |
Completed
|
No outcome recorded
|
| Phase 33 trials |
|
Phase 3
|
NCT07659574 |
Aug 2026 → Sep 2027 expected |
type 2 diabetes mellitus |
The United Bio-Technology (Hengqin) Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07648225 |
Jul 2026 → Sep 2027 expected |
obesity disorder |
The United Bio-Technology (Hengqin) Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07653477 |
Jul 2026 → Feb 2028 expected |
type 2 diabetes mellitus |
The United Bio-Technology (Hengqin) Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|